1 p.m.

Registration Desk Open – Marriott Marquis Washington (Level M1) one level below street level

Co-Chairs’ Welcoming Comments

• Cecilia Gonzalo, MBA – Partner, Oberland Capital
• Tim Watkins, MD, MS – Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences

Pioneer Sponsor Address

• Craig Conoscenti, MD, FCCP, ATSF – Therapeutic Area Head and Executive Director, Inflammation, Clinical Development and Medical Affairs Specialty, Boehringer Ingelheim Pharmaceuticals, Inc.

RIS Keynote Address: Using the Apple Ecosystem for Health Research

• Asha N. Chesnutt, MD – Clinical Specialist, Apple Health
• Russell Bowler, MD, PhD – Professor of Medicine, National Jewish Health

Panel: Patient Group Leaders from the ATS Public Advisory Roundtable

• Moderator: Lyn Baranowski, MBA – Chief Executive Officer, Avalyn Pharma
• Donna Appell, RN – Executive Director, Hermansky-Pudlak Syndrome Network
• Michele Manion – Executive Director, PCD Foundation
• Mary McGowan – Chief Executive Officer, Foundation for Sarcoidosis Research
• Jennifer Mefford – Vice President, Corporate Partnerships, Pulmonary Fibrosis Foundation
• Kari Luther Rosbeck – President and CEO, TSC Alliance

• NHLBI – Steve Flaim, PhD, FACC, FAHA – Senior Special Advisor & Investor-In-Residence, NHLBI, NIH NCATS
• Joshua Fessel, MD, PhD - Senior Clinical Advisor, Division of Clinical Innovation; National Center for Advancing Translational Sciences (NCATS); NIH
• NIH Foundation – Steve Hoffman, MS, BSc - Associate Vice President, Research Partnerships at Foundation for the National Institutes of Health
• BARDA – Kimberly Armstrong, PhD, MT (ASCP)- Director, Influenza and Emerging Infectious Diseases Division (IEIDD), BARDA, ASPR, DHHS

Welcome from the ATS President

• Gregory P. Downey, MD, ATSF - National Jewish Health

Co-Chair Address: State of Innovation and Investment

• Cecilia Gonzalo, MBA – Partner, Oberland Capital
• Tim Watkins, MD, MS – Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences

Showcase One: Asthma, COPD, and Airway Inflammation Innovators

• Moderator: Ted Reiss, MD, MBE, ATSF
• Avalo Therapeutics, Inc.
• Kinaset Therapeutics
• RAGE Biotech Pty Ltd
• ReAlta Life Sciences
• SpliSense

Panel Discussion: Venture Capital

• Moderator: Jamil Beg – Partner, 5AM Ventures
• Tiba Aynechi, PhD – General Partner, Norwest Venture Partners
• Christine Borowski, PhD – Vice President, Access Industries
• Cristina Ghenoiu, PhD – Principal, RA Capital
• Bert Kinsey, PhD, PharmD - Research Analyst, Principal - Eventide Asset Management
• Maneka Mirchandaney – Principal, Viking Global Investors
• Samantha Palmer, PhD, MBA - Executive Director, Business Development, Amgen Ventures

Showcase Two: Critical Care, Chronic Cough and Sleep Innovators

• Moderator: Courtney Crim, MD, ATSF
• Apnimed
• Atelerix Life Sciences
• KeViRx, Inc.
• Trevi Therapeutics
• Xequel Bio, Inc.

Fireside with the FDA: How Do We Accelerate Respiratory Discovery?

• Moderator: Robert J. Meyer, MD – Principal, Greenleaf Health
• Sally Seymour, MD – Office of Immunology and Inflammation - Division of Pulmonology, Allergy, and Critical Care (DPACC); US Food and Drug Administration
• Mary Tran Than Hai, MD - Deputy Director for Clinical, Office of New Drugs; U.S. Food and Drug Administration
• Onyeka Illoh, OD, MPH - Team Leader, Team Leader, Division of Clinical Outcome Assessment U.S. Food and Drug Administration

Showcase Three: : Technology Innovators: Devices, Digital, AI and More

• Moderator: Jason Kirkness, PhD, ATSF
• FluidIQ
• ImmuneIQ
• Samay
• Spiro Medical
• VIDA

RIS Success Story Presentation - By Invitation

• Peter M. Small, MD – Chief Medical Officer, Hyfe, Inc.

Panel: Business Development

• Moderator: Amanda Mason, PhD – Director, Business Development, Amgen
• Jane Escott, PhD – Director, Respiratory Search and Evaluation Leader, AstraZeneca
• Silke Hobbie, PhD – Global Head of Business Development & Licensing – Respiratory, Boehringer Ingelheim
• Christopher Mortko, PhD, MBA - Vice President, Head Search and Evaluation, Business Development & Licensing, Merck
• Eugene J. Sullivan, MD, FCCP – Chief Product Strategy Officer, Insmed
• Jeannie Rojas, PhD, MBA – Senior Director, Worldwide Business Development - GlaxoSmithKline
• Aryeh Fischer, MD - Clinical Development Lead, Lung Fibrosis, Bristol Myers Squibb

Showcase Four: Inflammation, Infectious Disease and Other Innovators

• Moderator: David Morris, MD
• Aerami Therapeutics
• Arrowhead Pharmaceuticals
• AuraVax Therapeutics, Inc.
• Rnatics
• Synairgen

Panel: Biomarkers and Innovation

• Moderator: Tim Watkins, MD, MS - Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
• Bastiaan Driehuys, PhD –Chief Scientific Officer, Polarean Imaging
• Jonathan G. Goldin, MD – Section Chief and Head of Radiology, UCLA Medical Center
• Sydney B. Montesi, MD – Massachusetts General Hospital
• Dave Morris, MD – President, Technologies and Therapeutics, Valo Health
• John Sundy, MD, PhD – Chief Medical Officer and Head of Research and Development, Seismic Therapeutic

Showcase Five: Fibrosis Innovators

• Moderator: Mary Strek, MD
• Atyr Pharma
• Avalyn Pharmaceuticals
• Lassen Therapeutics
• Pieris Pharmaceuticals
• Prosia
• Vicore Pharma

Closing Remarks and Sponsor Recognition

• Cecilia Gonzalo, MBA – Partner, Oberland Capital
• Tim Watkins, MD, MS - Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences